I am a Ph.D. candidate in the Pharmaceutical Outcome Research and Policy Program at the University of Washington. I hold a bachelors degree in biology from Boston University and a masters of public health from Columbia University.
My dissertation research is exploring the use of quantitative tools to aid in the selection and prioritization of publicly funded cancer clinical trials. Specifically, I am seeking to determine whether promising advances in value of information (VOI) analyses and risk prediction can be used to improve decision-making within a publicly funded cancer clinical trials co-operative group. This project will develop, test, and validate processes for rapidly estimating the expected risk and return for clinical trials proposals, and using these estimates explore how a portfolio optimization framework could improve allocations of limited public resources. This work is supported by an R36 Award from the Agency for Healthcare Research and Quality (AHRQ) and a Doctoral Dissertation Improvement Grant from the National Science Foundation (NSF).
I also work with Dr. David Veenstra on several projects related to the economic evaluation of whole genome/exome sequencing in the context of clinical care for patients with colon cancer. Before moving to Seattle, I worked as a biostatistician in Dr. Andrew Vickers’s research group at Memorial Sloan-Kettering Cancer Center, primarily focusing on the evaluation of novel biomarkers in prostate cancer screening and the clinical value of prediction models.
My long term research interests are in the development and real-world implementation of sophisticated decision analytical tools to help policymakers, patients, and providers in the face of uncertain and complex decisions in oncology.